Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ceryvyn Therapeutics Ltd. - Unsponsored ADR (CYVNY : OTC)

• Company Description    Opthea Limited is a biotechnology company. It develops and commercializes therapies primarily for eye disease principally in Australia. Opthea Limited is based in South Yarra, Australia. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $0.03 Daily Weekly Monthly 20 Day Moving Average: 19,012 shares Shares Outstanding: 171.00 (millions) Market Capitalization: $5.81 (millions) Beta: 1.45 52 Week High: $3.17 52 Week Low: $0.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.60% -13.24% 12 Week 61.90% 57.47% Year To Date 44.68% 33.69%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 505 LITTLE COLLINS STREET LEVEL 9 - MELBOURNE VICTORIA,C3 3000 AUS ph: 61-3-9826-0399 fax: - info@opthea.com http://www.opthea.com

• General Corporate Information    Officers Fred Guerard - Chief Executive Officer Jeremy Levin - Chairperson Thomas Reilly - Chief Financial Officer Julia Haller - Director Lawrence Gozlan - Director Peer Information Ceryvyn Therapeutics Ltd. - Unsponsored ADR (CORR.) Ceryvyn Therapeutics Ltd. - Unsponsored ADR (RSPI) Ceryvyn Therapeutics Ltd. - Unsponsored ADR (CGXP) Ceryvyn Therapeutics Ltd. - Unsponsored ADR (BGEN) Ceryvyn Therapeutics Ltd. - Unsponsored ADR (GTBP) Ceryvyn Therapeutics Ltd. - Unsponsored ADR (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68386J208 SIC: 2836 Fiscal Year Fiscal Year End: June Last Reported Quarter: - Next Expected EPS Date: 09/04/26 Share - Related Items Shares Outstanding: 171.00 Most Recent Split Date: (:1) Beta: 1.45 Market Capitalization: $5.81 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - - 03/31/26 - - 12/31/25 - - Current Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - - Quick Ratio 06/30/26 - - 03/31/26 - - 12/31/25 - - Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - - 12/31/25 - - Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©